Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide for GvHD Prophylaxis in Multiple Myeloma
NCT03700450Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Mar 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in multiple myeloma (MM), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: Chronic Graft-versus-Host Disease at 2 years and Progression-Free Survival at 2 years. Started Mar 2018; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03700450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700450.